Serum-free media formulations are cell line-specific and require optimization for microcarrier culture

Cytotherapy

Volumn 17, Issue 8, 2015, Pages 1152-1165

  Tan, Kah Yong ^a   Teo, Kim Leng ^a   Lim, Jessica F Y ^a   Chen, Allen K L ^a   Reuveny, Shaul ^a   Oh, Steve K W ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Mesenchymal stromal cell; Microcarrier; Serum free medium

Indexed keywords

ARTICLE; CELL ADHESION; CELL CULTURE; CELL EXPANSION; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL SPREADING; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MICROCARRIER CULTURE; MONOLAYER CULTURE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; BIOLOGICAL THERAPY; CULTURE TECHNIQUE; CYTOLOGY; PROCEDURES;

CULTURE MEDIUM;

CELL CULTURE TECHNIQUES; CELL LINE; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CULTURE MEDIA, SERUM-FREE; HUMANS; MESENCHYMAL STROMAL CELLS;

EID: 84937548719     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.05.001     Document Type: Article

References (77)

1. ClinicalTrials.gov; search for trials containing the term "Mesenchymal Stem Cells".
2. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
3. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109:235-242.
4. Anzalone R., Lo Iacono M., Corrao S., Magno F., Loria T., Cappello F., et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev 2010, 19:423-438.
5. Khan W.S., Adesida A.B., Tew S.R., Longo U.G., Hardingham T.E. Fat pad-derived mesenchymal stem cells as a potential source for cell-based adipose tissue repair strategies. Cell Prolif 2012, 45:111-120.
6. Pontikoglou C., Delorme B., Charbord P. Human bone marrow native mesenchymal stem cells. Regen Med 2008, 3:731-741.
7. Caplan A.I., Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
8. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012, 20:14-20.
9. Trounson A., Thakar R.G., Lomax G., Gibbons D. Clinical trials for stem cell therapies. BMC Med 2011, 9:52.
10. Wang S., Qu X., Zhao R.C. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012, 5:19.
11. Sharma R.R., Pollock K., Hubel A., McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 2014, 54:1418-1437.
12. Le Blanc K., Gotherstrom C., Ringden O., Hassan M., McMahon R., Horwitz E., et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79:1607-1614.
13. Wakitani S., Imoto K., Yamamoto T., Saito M., Murata N., Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002, 10:199-206.
14. Herrmann R., Sturm M., Shaw K., Purtill D., Cooney J., Wright M., et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol 2012, 95:182-188.
15. Kuzmina L.A., Petinati N.A., Parovichnikova E.N., Lubimova L.S., Gribanova E.O., Gaponova T.V., et al. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int 2012, 2012:968213.
16. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Med 1999, 5:309-313.
17. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
18. Koc O.N., Day J., Nieder M., Gerson S.L., Lazarus H.M., Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.
19. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
20. Tissue culture media for human ex vivo tissue and cell culture processing applications. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/010087gd.pdf.
21. FDA Grants 510(k) Clearance to Life Technologies Stem Cell Growth Medium. Available at: Accessed March 4, 2015. http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103302.pdf.
22. Dimarakis I., Levicar N. Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells 2006, 24:1407-1408.
23. Sotiropoulou P.A., Perez S.A., Salagianni M., Baxevanis C.N., Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006, 24:462-471.
24. Spees J.L., Gregory C.A., Singh H., Tucker H.A., Peister A., Lynch P.J., et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004, 9:747-756.
25. Jung S., Panchalingam K.M., Rosenberg L., Behie L.A. Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int 2012, 2012:123030.
26. An J.H., Park H., Song J.A., Ki K.H., Yang J.Y., Choi H.J., et al. Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice. Tissue Eng Part A 2013, 19:685-696.
27. Al-Saqi S.H., Saliem M., Quezada H.C., Ekblad A., Jonasson A.F., Hovatta O., et al. Defined serum- and xeno-free cryopreservation of mesenchymal stem cells. Cell Tissue Bank 2014, 16:181-193.
28. Gottipamula S., Muttigi M.S., Kolkundkar U., Seetharam R.N. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif 2013, 46:608-627.
29. Lindroos B., Boucher S., Chase L., Kuokkanen H., Huhtala H., Haataja R., et al. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy 2009, 11:958-972.
30. Gottipamula S, Muttigi MS, Chaansa S, Ashwin KM, Priya N, Kolkundkar U, et al.Large-scale expansion of pre-isolated bone marrow mesenchymal stromal cells in serum-free conditions [published online ahead of print March 12, 2013]. Tissue Eng Regen Med.
31. Kinzebach S., Bieback K. Expansion of Mesenchymal Stem/Stromal cells under xenogenic-free culture conditions. Adv Biochem Eng Biotechnol 2013, 129:33-57.
32. Meng G., Liu S., Rancourt D.E. Synergistic effect of medium, matrix, and exogenous factors on the adhesion and growth of human pluripotent stem cells under defined, xeno-free conditions. Stem Cells Dev 2012, 21:2036-2048.
33. Rajaraman G., White J., Tan K.S., Ulrich D., Rosamilia A., Werkmeister J., Gargett C.E. Optimization and scale-up culture of human endometrial multipotent mesenchymal stromal cells: potential for clinical application. Tissue Eng Part C Methods 2013, 19:80-92.
34. Hudson J.E., Mills R.J., Frith J.E., Brooke G., Jaramillo-Ferrada P., Wolvetang E.J., et al. A defined medium and substrate for expansion of human mesenchymal stromal cell progenitors that enriches for osteo- and chondrogenic precursors. Stem Cells Dev 2011, 20:77-87.
35. Chase L.G., Yang S., Zachar V., Yang Z., Lakshmipathy U., Bradford J., et al. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med 2012, 1:750-758.
36. Chase L.G., Lakshmipathy U., Solchaga L.A., Rao M.S., Vemuri M.C. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2010, 1:8.
37. McNiece I., Harrington J., Turney J., Kellner J., Shpall E.J. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy 2004, 6:311-317.
38. Swamynathan P., Venugopal P., Kannan S., Thej C., Kolkundar U.K., Bhagwat S., et al. Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton's jelly derived mesenchymal stem cells? A comparative study. Stem Cell Res Ther 2014, 5:88.
39. Genser-Nir M., Daniliuc S., Tevrovsky M., Fiorentini D. Toward a serum-free, xeno-free culture system for optimal growth and expansion of hMSC suited to therapeutic applications. BMC Proceedings 2013, 7(Suppl 6):P6.
40. Cui L., Zhou X., Li J., Wang L., Wang J., Li Q., et al. Dynamic microRNA profiles of hepatic differentiated human umbilical cord lining-derived mesenchymal stem cells. PLoS One 2012, 7:e44737.
41. Jung S., Sen A., Rosenberg L., Behie L.A. Human mesenchymal stem cell culture: rapid and efficient isolation and expansion in a defined serum-free medium. J Tissue Eng Regen Med 2012, 6:391-403.
42. Crapnell K., Blaesius R., Hastings A., Lennon D.P., Caplan A.I., Bruder S.P. Growth, differentiation capacity, and function of mesenchymal stem cells expanded in serum-free medium developed via combinatorial screening. Exp Cell Res 2013, 319:1409-1418.
43. Apel A., Groth A., Schlesinger S., Bruns H., Schemmer P., Buchler M.W., et al. Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium. Exp Cell Res 2009, 315:498-507.
44. Rowley J.A.E., Campbell A., Brandwein H., Oh S. Meeting Lot-Size Challenges of Manufacturing Adherent Cells for Therapy. Bioprocess Int 2012, 10:16-22.
45. Subbanna P.K. Mesenchymal stem cells for treating GVHD: in-vivo fate and optimal dose. Med Hypotheses 2007, 69:469-470.
46. Hervy M., Weber J.L., Pecheul M., Dolley-Sonneville P., Henry D., Zhou Y., et al. Long term expansion of bone marrow-derived hMSCs on novel synthetic microcarriers in xeno-free, defined conditions. PLoS One 2014, 9:e92120.
47. Goh T.K., Zhang Z.Y., Chen A.K., Reuveny S., Choolani M., Chan J.K., et al. Microcarrier culture for efficient expansion and osteogenic differentiation of human fetal mesenchymal stem cells. Biores Open Access 2013, 2:84-97.
48. Lam A.T., Li J., Chen A.K., Reuveny S., Oh S.K., Birch W.R. Cationic surface charge combined with either vitronectin or laminin dictates the evolution of human embryonic stem cells/microcarrier aggregates and cell growth in agitated cultures. Stem Cells Dev 2014, 23:1688-1703.
49. Chen A.K., Reuveny S., Oh S.K. Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction. Biotechnol Adv 2013, 31:1032-1046.
50. Chen A.K., Chew Y.K., Tan H.Y., Reuveny S., Weng Oh S.K. Increasing efficiency of human mesenchymal stromal cell culture by optimization of microcarrier concentration and design of medium feed. Cytotherapy 2014, 17:163-173.
51. Tarle S.A., Shi S., Kaigler D. Development of a serum-free system to expand dental-derived stem cells: PDLSCs and SHEDs. J Cell Physiol 2011, 226:66-73.
52. Jung S., Sen A., Rosenberg L., Behie L.A. Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. Cytotherapy 2010, 12:637-657.
53. Bray L.J., Heazlewood C.F., Atkinson K., Hutmacher D.W., Harkin D.G. Evaluation of methods for cultivating limbal mesenchymal stromal cells. Cytotherapy 2012, 14:936-947.
54. Beane O.S., Fonseca V.C., Cooper L.L., Koren G., Darling E.M. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One 2014, 9:e115963.
55. Guillot P.V., Gotherstrom C., Chan J., Kurata H., Fisk N.M. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 2007, 25:646-654.
56. Wegmeyer H., Broske A.M., Leddin M., Kuentzer K., Nisslbeck A.K., Hupfeld J., et al. Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev 2013, 22:2606-2618.
57. Jung S., Panchalingam K.M., Wuerth R.D., Rosenberg L., Behie L.A. Large-scale production of human mesenchymal stem cells for clinical applications. Biotechnol Appl Biochem 2012, 59:106-120.
58. Santos F., Andrade P.Z., Abecasis M.M., Gimble J.M., Chase L.G., Campbell A.M., et al. Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods 2011, 17:1201-1210.
59. Sun L.Y., Hsieh D.K., Syu W.S., Li Y.S., Chiu H.T., Chiou T.W. Cell proliferation of human bone marrow mesenchymal stem cells on biodegradable microcarriers enhances in vitro differentiation potential. Cell Prolif 2010, 43:445-456.
60. Hupfeld J., Gorr I.H., Schwald C., Beaucamp N., Wiechmann K., Kuentzer K., et al. Modulation of mesenchymal stromal cell characteristics by microcarrier culture in bioreactors. Biotechnol Bioeng 2014, 111:2290-2302.
61. Gottipamula S., Sharma A., Krishnamurthy S., Majumdar A.S., Seetharam R.N. Human platelet lysate is an alternative to fetal bovine serum for large-scale expansion of bone marrow-derived mesenchymal stromal cells. Biotechnol Lett 2012, 34:1367-1374.
62. Jenhani F., Durand V., Ben Azouna N., Thallet S., Ben Othmen T., Bejaoui M., et al. Human cytokine expression profile in various conditioned media for in vitro expansion bone marrow and umbilical cord blood immunophenotyped mesenchymal stem cells. Transplant Proc 2011, 43:639-643.
63. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007, 40:785-791.
64. Crespo-Diaz R., Behfar A., Butler G.W., Padley D.J., Sarr M.G., Bartunek J., et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 2011, 20:797-811.
65. Hemeda H., Giebel B., Wagner W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy 2014, 16:170-180.
66. Dos Santos F., Campbell A., Fernandes-Platzgummer A., Andrade P.Z., Gimble J.M., Wen Y., et al. A xenogeneic-free bioreactor system for the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnol Bioeng 2014, 111:1116-1127.
67. Dolley-Sonneville P.J., Romeo L.E., Melkoumian Z.K. Synthetic surface for expansion of human mesenchymal stem cells in xeno-free, chemically defined culture conditions. PLoS One 2013, 8:e70263.
68. Schiller M., Franz S., Heyder P., Voll R.E., Gaipl U.S., Lorenz H.M., et al. Hypothesis: human serum-borne albumin bound lipids promote cellular survival after apoptosis induction by a variety of stimuli. Apoptosis 2008, 13:319-328.
69. Ishima Y., Akaike T., Kragh-Hansen U., Hiroyama S., Sawa T., Maruyama T., et al. Effects of endogenous ligands on the biological role of human serum albumin in S-nitrosylation. Biochem Biophys Res Commun 2007, 364:790-795.
70. Keenan J., Doherty G., Clynes M. Separation of growth-stimulating activity of BSA fraction V from the bulk of albumin using Heparin Sepharose Chromatography. Cytotechnology 1995, 19:63-72.
71. Keenan J., Dooley M., Pearson D., Clynes M. Recombinant Human Albumin in Cell Culture: Evaluation of Growth-Promoting Potential for NRK and SCC-9 Cells In Vitro. Cytotechnology 1997, 24:243-252.
72. Schop D., van Dijkhuizen-Radersma R., Borgart E., Janssen F.W., Rozemuller H., Prins H.J., et al. Expansion of human mesenchymal stromal cells on microcarriers: growth and metabolism. J Tissue Eng Regen Med 2010, 4:131-140.
73. Hewitt C.J., Lee K., Nienow A.W., Thomas R.J., Smith M., Thomas C.R. Expansion of human mesenchymal stem cells on microcarriers. Biotechnol Lett 2011, 33:2325-2335.
74. Timmins N.E., Kiel M., Gunther M., Heazlewood C., Doran M.R., Brooke G., et al. Closed system isolation and scalable expansion of human placental mesenchymal stem cells. Biotechnol Bioeng 2012, 109:1817-1826.
75. Yang Y., Rossi F.M., Putnins E.E. Ex vivo expansion of rat bone marrow mesenchymal stromal cells on microcarrier beads in spin culture. Biomaterials 2007, 28:3110-3120.
76. Zhou Y., Yan Z., Zhang H., Lu W., Liu S., Huang X., et al. Expansion and delivery of adipose-derived mesenchymal stem cells on three microcarriers for soft tissue regeneration. Tissue Eng Part A 2011, 17:2981-2997.
77. Elseberg C.L., Leber J., Salzig D., Wallrapp C., Kassem M., Kraume M., et al. Microcarrier-based expansion process for hMSCs with high vitality and undifferentiated characteristics. Int J Artif Organs 2012, 35:93-107.